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Thursday, October 5, 2017: 12:30 PM Background. In 2013, the US Preventive Services Task Force made a grade B recommendation to offer HCV screening for at-risk individuals and baby boomers (born between 1945 and 1965) . However, only 50% of HCV-positive individuals are aware they are infected, and far fewer attend an outpatient appointment and are initiated on treatment (Linkage to Care: LTC). The aim of this study is to assess the factors affecting LTC among HCV positives in a suburban tertiary medical center on Long Island, NY.
Methods. A retrospective chart review was performed on all patients with ICD-9 or 10 diagnostic codes for HCV positive antibody from January 2016 to March 2017 at Stony Brook University Hospital. Data were collected for HCV RNA, LTC, demographics, insurance and employment status, psychiatric diagnosis, comorbid medical conditions, substance use disorder, injection drug use, liver and kidney function, level of fibrosis.
Results. A total of 155 cases (61.9% male; mean age 53.9 years) had a positive HCV antibody, 110 (71%) had a follow-up HCV RNA test and 35.1% were LTC. The comorbidities present in this cohort were psychiatric disease (54.9%), cirrhosis (22.6%), HBV infection (14.1%) and HIV (8.5%). In the univariate analysis, new inpatient HCV diagnosis (OR = 0.09, 95% CI: 0.02-0.36, P = 0.001), employment (OR = 3, 95% CI: 1.01-8.95, P = 0.049) and history of substance use disorder (OR = 0.38, 95% CI: 0.15-0.96, P = 0.043) were associated with LTC. In the logistic regression analysis, inpatient HCV diagnosis was negatively correlated with LTC (OR: 0.03, 95% CI: 0.002-0.41, P = 0.009). Two hot spots of HCV infection were identified in south central Suffolk County.
Conclusion. In this population, new inpatient HCV diagnosis and history of substance use disorder were less likely to have LTC, whereas those employed were more likely to have LTC. Innovative interventions in the inpatient setting may be beneficial for newly diagnosed HCV cases to improve LTC after discharge.
Disclosures. Background. The newly introduced direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection have substantially higher cure rates and less side effects compared with previous regimens. However, in order to achieve optimal patient engagement in HCV treatment, it's highly imperative to develop comprehensive HCV treatment programs which provide optimal services that help navigate patients through a challenging healthcare system.
Methods. In 2014, a comprehensive HCV treatment program employing a multidisciplinary team service was created at our Ryan White sponsored clinic in Metro-Detroit. The team which included infectious disease physicians, nurse practitioners and social workers aimed at identifying and addressing the socioeconomic barriers among our underserved HCV-infected population. We present the characteristics of HCV patients enrolled in the program as well as assess the sustained viral response rates (SVR) among patients treated for HCV infection between October 2014 and January 2017. May 10, 2017 was the date of last recorded SVR for patients who completed their DAA treatment.
Results. Up to May 10, 2017, the program included 317 patients with HCV infection. The mean age of patients was 59 years (SD = 8). Around 68% of the cohort were males and 89% were African Americans. Of 317 patients, 61 % had Medicaid only, 14% had Medicare only and 18% had Medicare and Medicaid. The 2 most common modes of HCV transmission among our cohort was IV drug use (60%) and male to male sex (11%). Most of the patients had genotype 1a (62%) and approximately 37% of them were co-infected with HIV. One-hundred and sixty patients (51%) received or started treatment with DAA; ledipasvir/sofosbuvir being the most commonly prescribed regimen (126/160; 79%). Among 109 HCV infected patients who were expected to finish their DAA treatment 12 weeks before the date of last recorded SVR, 107 (98%) completed treatment. SVR was achieved in 100 % of patients who completed their treatment.
Conclusion. Despite the state Medicaid restrictions, the high DAA costs, and the challenging socioeconomic status of our population, our program was able to achieve impressive SVR rates comparable to other HCV management programs in the US.
Disclosures. All authors: No reported disclosures. Background. Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in the US. It is the leading cause of complications from chronic liver disease and the most common indication for liver transplants among US adults. National guidelines recommend one-time birth cohort based screening for adults born from 1945 to 1965 regardless of risk factors for blood-borne infections. A magnitude assessment of infectious disease outpatients demonstrated a birth cohort based screening rate of 38%. Prior quality improvement projects at other institutions have resulted in significant improvements in screening rates, with up to 90% of eligible individuals being screened. We aim to increase HCV screening by 20% amongst Primary Care Internal Medicine (PCIM) patients born from 1945 to 1965 at Mayo Clinic Rochester over a 6 month period.
Improving Hepatitis C Screening Rates in Primary Care
Methods. The baseline screening rate over a 2-year period (January 1, 2015-December 31, 2016) was extracted from medical records. An anonymous online survey was created and sent to PCIM providers to assess their comfort with screening guideline recommendations and current perceived practices, as well as perform a stakeholder analysis to identify current barriers to screening. A reminder email was sent 3 weeks after the initial invitation.
Results. The baseline screening rate was 6% (769 of 12,269 eligible visits). We attained a 30% (17/57) survey response rate after 4 weeks. Only 6% (1/17) reported screening all patients based on guideline recommendations. We found that 35% of providers are unsure who is eligible for screening. The majority (56%) cited not remembering to discuss screening, and only 18% felt very confident with their understanding of the guidelines. Other reasons for not screening per Figure 1 . All providers stated they would screen more patients if there was a screening prompt, and 71% felt that providers needed more education.
Conclusion. Based on the results we implemented an electronic medical record tool to prompt providers to order HCV screening on patients eligible by birth cohort, who had not been previously screened, and did not have known HCV infection. Education was provided via a divisional newsletter. We are currently collecting data to analyze screening rates 6 months after implementation of our intervention.
Figure 1
Disclosures. All authors: No reported disclosures. October 5, 2017: 12:30 PM Background. Directly acting agents (DAA) have revolutionized the treatment of Hepatitis C infection. However the access to appropriate drugs has been a barrier to therapy. Our objective of this study was to find the impact of insurance type and treatment regimen on outcome in patients with hepatitis C.
Impact of Insurance and Treatment Regimens on HCV
Methods. We have maintained a database of patients with HCV infection who were seen at our outpatient infectious disease clinic. We conducted a retrospective review of 160 patients who have been following since [2005] [2006] . In addition to baseline data, we also collected data on treatment status, regimens, outcome, insurance and reasons for no treatment. Statistical analyses included chi-square tests for categorical variables and ANOVA for numerical variables. This study was approved by the institutional review board.
Results. Of the 160 charts reviewed, we had complete records of 40 patients who had a median follow-up period of 12 years. Among them 75% of the patients had HCV genotype 1 (1a or 1b). Liver biopsy was available only for 50% patients which showed 32.5% had early stage (0-2) and 27.5% had late stage (3-4) fibrosis. Most of the patients (17) were treated with older therapies (peg-interferon alpha with or without boceprevir or telaprevir) and 7 with newer DAA combinations, whereas 16 patients did not receive treatment. All patients with private insurance received treatment whereas a large proportion with public aid did not (100% vs. 57%, P = 0.002). Total 19 of 28 treated patients achieved a sustained viral response beyond 2 years. All 7 patients who received newer DAAs were cured. Among the 16 patients who did not receive antiviral treatment, 5 (30%) had a poor outcome including liver cirrhosis (1), hepatocellular carcinoma (2 HCC), and death (2) compared with only 2 patients (1 cirrhosis, 1 HCC) in treated group (P <0.001). None of the patients in treated group died.
Conclusion. In this study, patients who did not have access to appropriate antiviral therapy had worse outcome. The main determinant for poor access to treatment was the type of insurance. It is important to improve access to treatment for all patients with HCV infection which can reduce the rate of progression to advanced liver disease and mortality.
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